Urinary Tract Infections Market

Global Urinary Tract Infections Market Size (2023 to 2028)

The global urinary tract infections market is forecasted to grow at a CAGR of 2.14% from 2023 to 2028. The market size is estimated to value USD 11.68 billion by 2028 from USD 10.51 billion in 2023.

Urinary Tract Infection is an infection that affects parts of the urinary tract. When it affects the lower urinary tract, it is called a bladder infection or cystitis; when it affects the upper urinary tract, it is called a kidney infection or pyelonephritis. A UTI can happen anywhere in your urinary tract. The urinary tract comprises your kidneys, ureters, bladder, and urethra. Most UTIs only involve the urethra and bladder in the lower tract. However, UTIs can involve the ureters and kidneys in the upper tract. Although upper tract UTIs are rarer than lower tract UTIs, they’re also usually more severe. UTI symptoms are burning, increased frequency of urination, bloody urine, pelvic pain in women, rectal pain in men, and urine that looks like cola or tea. Today Urinary Tract Infections are most common in women. 

MARKET DRIVERS:

The growing disease burden and diagnosis of the disease are majorly driving the global urinary tract infections market growth.

To address the growing need for treatment procedures for UTIs, the market participants are investing hefty amounts and conducting R&D around combination therapies. This is expected to result in market growth during the forecast period. Furthermore, with the launch of new drugs for multiple indications under urinary tract infections and label expansion for existing drugs, the market is expected to boost further.

The several risk factors and the need for treatment to propel urinary tract infections market growth.

The most common cause of infection is E coli, though other fungi or bacteria may rarely be the cause. Risk factors include female anatomy, diabetes, obesity, sexual intercourse, and family history. Although sexual intercourse is a risk factor, urinary tract infections are not categorized as sexually transmitted infections. If a kidney infection occurs, it usually follows a bladder infection and results from infection, which is blood-borne. Diagnosis in young, healthy women can be based alone on symptoms. Diagnosis is difficult for those with vague symptoms since bacteria may be present without an infection. A urine culture may be helpful in complicated cases or when conventional treatments fail.

The recent research and developments in UTI services support the growth rate of the urinary tract infections market.

While treating UTIs may not be challenging, patients and doctors may occasionally struggle to avoid UTI recurrence. The pathophysiology, risk factors, biomarkers, and prevention of recurrent UTIs have all been recently discovered by research, among other unique; therefore, there is a lot of interest in and study on the prevention of recurrent UTIs. According to the recommendations of the European Association of Urology, the following steps should be taken in this order to prevent recurring UTIs, Behavioral adjustments and avoiding risk factors, nonantimicrobial interventions, and prophylactic use of antibiotics. The most well-known method of preventing recurrent UTIs may be drinking cranberry juice. Other methods include replacing lost estrogen with either topically applied vaginal cream or oral medications, restoring the unhealthy urogenital flora from uropathogens with Lactobacilli, and preventing UTI recurrence by employing a vaccination to boost active acquired immunity against uropathogenic along with Continuous antimicrobial prophylaxis can be provided for a very long time to prevent UTI recurrence.

MARKET RESTRAINTS:

Complicated regulatory monitoring hampers the urinary tract infections market. Several companies have prevented or reduced the research and development activities in advancing antibiotics as they have a low return on investments. The investments required for the research and development activities for new drugs and antibiotics are comparatively low. This factor is anticipated to limit the market grIn addition, lack. Lack of awareness regarding the frequent urinary tract infections in developed and underdeveloped countries is restraining market growth. The clinical trials for preparing antibacterial drugs are challenging and require an instructive, ethical, and scientific approach. The mentioned above factor obstructs market growth.

Impact of COVID-19 on the global urinary tract infections market:

The novel coronavirus (COVID-19), announced as a pandemic by WHO, infected millions and caused thousands to die. The common comorbidity in COVID-19-positive patients is diabetes, chronic lung disease, and hypertension. People 60 years and above or suffering from health conditions such as diabetes, heart or lung disease, which affects their immune system, are more likely to suffer from COVID-19. Not only efficient in causing respiratory illness, but COVID-19 may also damage the human body's organs and urogenital systems. In addition, COVID-19 sensitivity may result in bladder dysfunction. During the COVID-19 pandemic, priority has been given to treating patients with coronavirus and given less priority to patients suffering from other diseases, which resulted in the declining growth rate of the urinary tract infections market. However, considering the factors such as the reduced impact of COVID-19 and the growing adoption of new normalization, the global market for urinary tract infections is projected to grow at a healthy CAGR in the coming years.

REPORT COVERAGE:

This research report on the global urinary tract infections market has been segmented and sub-segmented based on medication, type of indication, and region.

Urinary Tract Infections Market – By Type of Medication:

• Penicillin & Combinations 
  • Amoxicillin
  • Amoxicillin-Clavulanate Potassium combination
• Quinolones             
  • Ciprofloxacin
  • Levofloxacin
  • Norfloxacin
  • Nalidixic Acid
• Aminoglycoside-Antibodies             
  • Gentamicin
  • Amikacin
• Cephalosporin       
  • Ceftriaxone
  • Cefixime
  • Cefuroxime
  • Cephalexin
• Sulphonamides     
  • Sulfamethoxazole
  • Trimethoprim combination
• Azoles & Amphotericin B  
• Tetracycline           
  • Doxycycline
  • Nitrofurans
• Nitrofurans 

Based on the type of medication, the quinolones segment is expected to lead the global urinary tract infection market, holding 37.7% of the market in 2022. Many physicians suggest that patients who intake quinolones get rid of their infection quickly. In addition, the several advantages associated with quinolones drive segment growth. For instance, Quinolones have been favored as antibiotics for over five decades because of their high potency, broad spectrum of activity, favorable bioavailability, convenient formulations, and high serum concentrations, as well as a comparatively low incidence of side effects. 

The penicillin and combinations segments are predicted to grow at the highest CAGR growth rate during the forecast period. Additionally, the various applications of penicillin support segment growth. For instance, many bacterial infections are treated with penicillin, including meningitis, pneumonia, gonorrhea, syphilis, and endocarditis. In addition, penicillin is among the most used antibiotics worldwide, further supporting segmental growth.

Urinary Tract Infections Market – By Type of Indication:

• Uncomplicated UTI
• Complicated UTI   
• Recurring Complicated UTI               
• Neurogenic Bladder Infection  

Based on the indication, the complicated UTIs segment dominates the UTI and accounts for holding most of the market share. However, the segment growth depends on mushrooming drug-resistant bacteria and the enormous usage of antibiotics. In addition, many medical professionals prescribe quinolones for treating complicated urinary tract infections among patients—the regularity of complicated UTIs escalates throughout the forecasting period. According to the Queensland Pediatric Factsheet 2019, around 1 in 10 girls and 1 in 50 boys suffer from urinary tract infections by seven years of age.

However, the recurring complicated UTI segment is also expected to have a sizable revenue during the forecast period as it is relatively common for patients of complicated UTI to have a recurring problem. This recurrence is because Complicated UTIs can harm the body and increase the likelihood of therapy failures and recurrence.

Urinary Tract Infections Market – By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

The Asia Pacific urinary tract infections market had the largest share of the worldwide market in 2022 and is also the fastest-growing region, owing to factors such as rising rate of diagnostics, gradual adoption of improved technologies, emerging healthcare infrastructures, and increased disposable income. In addition, the growing support from government reimbursements in countries such as China, India, Japan, and South Korea is expected to contribute to the growth of the UTI market in the Asia-Pacific region. Furthermore, the growing geriatric population and the Growing need for affordable diagnostics and UTIs in pregnant women are driving the market in the region. 

The urinary tract infections market in North America is expected to be driven by the high disease burden, rising rates of diabetes and kidney stones, rapid advancements in UTI diagnostic techniques, accessibility to infrastructure, rising geriatric population, rising healthcare costs, and the discovery of novel classes of antibiotics for urinary tract infections, in countries such as the U.S. and Canada.

On the other hand, the European urinary tract infections market is also growing due to increasing expenditure toward better healthcare systems, key market competitors, rising disposable incomes, and incidences of diseases in the populations. 

The Latin American urinary tract infections market is anticipated to hold a considerable share of the global market in the coming years.

The urinary tract infections market in MEA is estimated to showcase a steady CAGR during the forecast period.

KEY PARTICIPANTS IN THE MARKET:

Some of the noteworthy companies leading the global urinary tract infections market profiled in this report are Pfizer, Inc., AstraZeneca plc, Johnson & Johnson, Novartis International AG., F. Hoffmann La Roche Ltd., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, and Cipla Ltd.

RECENT MARKET HAPPENINGS:

• In December 2022, the FDA approved BRIUMVITM (ublituximab-xiiy) for treating individuals with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome relapsing-remitting disease, and active secondary progressive illness, according to TG Therapeutics, Inc.
• In December 2022, the clinical trial for the precision medicine company's Unyvero urinary tract infection (UTI) drug was successfully concluded, with encouraging results and plans to submit to the FDA. However, ob-gyns still face many difficulties in accurately diagnosing complex UTIs. For example, pathogenic microbial species may go unnoticed for various reasons, and complicated polymicrobial illnesses may be particularly tough for analysis to show. In addition, microbiological cultures require several days to generate data.
• In December 2022, Brii Biosciences Limited, a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, announced progress against its strategic clinical development priorities, including various updates across its pipeline of candidates for infectious diseases and central nervous system diseases.
• In September 2020,  Spero Therapeutics Inc. announced the completion of patient registration in its Phase-3 clinical trial ADAPT-PO of tebipenem HBr. For treating patients suffering from complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). The test-of-cure (TOC) visit in the microbiological-intent-to-treat (micro-ITT) group showed that tebipenem HBr was non-inferior compared to ertapenem concerning the trial's primary goal, overall response. 
• In December 2019, Johnson & Johnson acquired TARIS Biomedical LLC. TAR-200, the leading clinical-stage product, uses the proprietary TARIS system that looks like a silicone-based drug delivery device and ensures the ongoing release of medication into the bladder.
• In October 2019, Cipla acquired Elores from Venus Remedies Ltd. Elores drug for treating life-threatening infections, and the medicine is to fight against antimicrobial resistance. According to the latest Phase-3 clinical study, Elores proved to be primary to meropenem for treating complicated urinary tract infections.
• In July 2019, Pfizer Inc. completed its acquisition of Array BioPharnma Inc. Array BioPharma became a part of Pfizer, adding a splendid portfolio, including the approved combined usage BRAFTOVI and MEKTOVI.